Aortic Valve Disease
Conditions
Brief summary
Transcatheter aortic valve replacement (TAVR) has became an important treatment of severe aortic stenosis (AS). Several randomized clinical trials showed that TAVR was non-inferior or superior to surgical aortic valve replacement (SAVR). However, many different issues have emerged: TAVR in younger patients? valve leaflet thrombosis? transcatheter valve durability? coronary reaccess after TAVR? TAVR in bicuspid aortic valve? TAVR in aortic regurgitation? etc. Hence, a prospective, multicenter database is created to provide the real-word data for these questions.
Interventions
patients with severe aortic valve disease underwent transcatheter heart valve
Sponsors
Nanjing First Hospital, Nanjing Medical University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Clinical diagnosis of severe aortic stenosis or aortic regurgitation 2. Patients undergo transcatheter aortic valve replacement
Exclusion criteria
patients refuse the clinical follow-up
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| all-cause death during follow-up | 5 years | all-cause death during 5-year follow-up |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| cardiac death during follow-up | 5 years | Cardiac death during 5-year follow-up |
Countries
China
Contacts
Primary ContactJun-Jie Zhang, MD
Backup ContactJing Kan, MPH
Outcome results
None listed